IDORSIA AG SF-,05
1,59€
+0,21 (+14,76%)
11.12.2024, 23:00:00 Uhr
WKN: A2DTEB ISIN: CH0363463438 Wertpapiertyp: Aktie Währung: Euro
- 1T
- 1W
- 1M
- 3M
- 6M
- 1J
- 3J
- 5J
- 10J
- Max
Weltmärkte
- DAX ® +21,06 +0,10% 20.420,22
- MDAX ® +73,68 +0,27% 26.929,05
- TecDAX ® -3,32 -0,09% 3.548,94
- E-STOXX 50 ® +7,61 +0,15% 4.959,35
- NASDAQ 100 +395,80 +1,85% 21.763,98
- HANG SENG +229,13 +1,14% 20.397,05
Kursperformance
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Tag | 1,59€ | +14,76% |
| 1 Woche | 1,05€ | +51,81% |
| 1 Monat | 1,00€ | +59,24% |
| 6 Monate | 2,26€ | -29,59% |
| Lfd. Jahr (YTD) | 2,31€ | -30,91% |
| 1 Jahr | 2,15€ | -25,86% |
| 3 Jahre | 15,77€ | -89,90% |
| 5 Jahre | 26,35€ | -93,95% |
Kursdaten
| Kurs | 1,59€ |
| Eröffnung | 1,63€ |
| Geld | 1,50€ |
| Brief | 1,53€ |
| Tages-Hoch | 1,63€ |
| Tages-Tief | 1,59€ |
| 52 Wochen-Hoch | 3,52€ |
| 52 Wochen-Tief | 0,69€ |
| Allzeit-Hoch | 31,65€ |
| Allzeit-Tief | 0,69€ |
Nachrichten
- GlobeNewswire: New data with daridorexant to be presented at SLEEP 2024 - 03.06.2024, 07:00:00 Uhr
- GlobeNewswire: Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024 - 31.05.2024, 07:00:00 Uhr
- GlobeNewswire: Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders - 23.05.2024, 07:00:00 Uhr
- GlobeNewswire: Idorsia announces changes to Idorsia Executive Committee and Board of Directors - 21.05.2024, 07:00:00 Uhr
- GlobeNewswire: Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor - 21.05.2024, 06:50:00 Uhr
- GlobeNewswire: Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value - 21.05.2024, 06:40:00 Uhr
- GlobeNewswire: Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call - 14.05.2024, 17:45:00 Uhr
- GlobeNewswire: Bondholders approve amended terms of the 2024 convertible bonds - 06.05.2024, 18:35:00 Uhr
- GlobeNewswire: Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond - 01.05.2024, 18:00:00 Uhr
- GlobeNewswire: JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension - 26.04.2024, 07:00:00 Uhr
